Clinical trial · no report yet · Phase 3

TRIPLEX

Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer

NCT05223647 ↗
Terminated
Norwegian University of Science and Technology
Focused

We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Preliminary discovery

Commentary in our index that names this trial so far

Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.

Channel	Found
X threads	2
Bluesky threads	1

The trial

ClinicalTrials.gov

Official title: Randomized Phase III Trial Investigating the Survival Benefit of Adding Thoracic Radiotherapy to Durvalumab (MEDI4736) Immunotherapy Plus Chemotherapy in Extensive Stage Small-cell Lung Cancer
Phase: Phase 3
Status: Terminated
Conditions: Small-cell Lung Cancer
Interventions: Thoracic radiotherapy; Chemo-immunotherapy
Arms: Chemo-immunotherapy plus thoracic radiotherapy · Experimental
Chemo-immunotherapy · Active comparator
Enrollment: 239
Primary outcomes: Change in 1-year overall survival
Sponsor: Norwegian University of Science and Technology with St. Olavs Hospital, Haukeland University Hospital, University Hospital of North Norway, Alesund Hospital, Helse Stavanger HF, Oslo University Hospital, Helse Nord-Trøndelag HF, Helse Fonna, Drammen sykehus, University Hospital, Akershus, Erasmus Medical Center, Sahlgrenska University Hospital, Karolinska University Hospital, Gävle Hospital, Sykehuset Innlandet HF, North Estonia Medical Centre, Nordlandssykehuset HF, Landspitali University Hospital, Lund University Hospital, University Hospital, Linkoeping
Start: Jan 11, 2022
Primary completion: Sep 4, 2025
Results posted: No
Registry record: NCT05223647 · updated Jan 28, 2026